Viadur

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com) has announced the addition of Business Development and R&D Database: Prostate Cancer to their offering.

A unique CD-ROM database has been released to enable independent and unbiased analysis of prostate cancer therapeutics progress and pitfalls, as well as competition and business opportunities. The information in the database has carefully been selected and structured to provide the most optimal and time saving platform to work from. The database contains extensive corporate, R&D, patent and business information. It includes extensive presentations of more than 200 selected companies activities in this field. In total, the database includes more than 3500 records from a multitude of information sources and 5000 related patents.

Generally, the database is structured into four sections:

--R&D activities

--Patents

--Collaborations

--Company profiles

The R&D information is structured into 11 searchable segments:

--Investigator

--Drug name

--Combinatory drugs

--Developmental stage

--Indication

--Sub-indication

--Therapy given

--Drug Effects

--Mechanisms/Targets

--General comments

--Source of data

The collaboration information is structured into 5 searchable segments:

--Collaborators

--Product

--Developmental stage

--Type of collaboration

--Type of terms

The database will help in:

--Tracking and describing cutting edge companies, therapies and new technologies

--Assesing the development status of competing drugs

--Allowing users to view comprehensive company pipelines.

--Rapid identification of partners & competitors

--Laying down a comprehensive framework for further analysis of the field

--Producing presentations surrounding the development of cancer therapeutics

--Identifying emerging cancer products & key areas of pharmaceutical R&D

Some of the drugs included in the database:

Avodart, Zoladex, Proscar, Casodex, Taxotere, Satraplatin, Plenaxis, EULEXIN, Trelstar Depot, Trelstar LA, Viadur, Gleevec, Avastin, Herceptin, Atrasentan, Acapodene, Actimid, OSI-461, Revimid, Eladem, GTI-2501, ILX-651, calcitrol, Genasense, Provenge , GVAX, SGN-15, Thalomid, Velcade, Lupron Depot, Histrelin, Eligard, ILX651, Vitaxin, J591, CG7870, BBR-3576, PCK3145, Leuvectin, Leuprolide, ProMaxx-100, Osaterone, Prinomastat, BLP25, Metaret, Chimax, Drogenil, Flutamide, EULEXIN, Onconase, IM862, MDX-010, Erbitux, Eladem, GTI-2040, Apomine, Eflornithine, Doxil, GTI-2501, Thalidomide, TG4010, KRX-0401, Yondelis, TRICOM Vaccine, Zarnestra

Some of the companies included in the database:

Aventis, Aeterna Laboratories Inc, Abbott Laboratories, Celgene, Cell Genesys, Cytogen Corporation, Dendreon, GlaxoSmithKline, GTx, Inc, Medimmune, Millennium Pharmaceuticals, Inc, Procyon BioPharma, Novacea Inc., Teikoku Hormone, Pfizer (Pharmacia), Paladin Labs/ Hydro Med Sciences, Novartis, Praecis Pharmaceuticals, Biomira, Spectrum Pharmaceuticals, ALZA, Medarex, ImClone,. BMS, Merck, Immuno-Designed Molecules (IDM), Lorus Therapeutics, ILEX Oncology, Keryx Biopharmaceuticals

For more information visit http://www.researchandmarkets.com/reports/c4935

COPYRIGHT 2004 Business Wire
COPYRIGHT 2004 Gale Group